MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
MaxCyte (NASDAQ: MXCT) will release fourth quarter and full year 2025 financial results after U.S. market close on March 24, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MaxCyte (NASDAQ: MXCT) will release fourth quarter and full year 2025 financial results after U.S. market close on March 24, 2026. Management will host a conference call at 4:30 p.m. ET the same day to discuss results.
Investors must register online to join the call; a live and archived webcast will be available in the company’s Events section at the investor website.
Details
News Market Reaction – MXCT
On Feb 24, the first trading day after this news, MXCT closed 5.01% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Earnings release date
- March 24, 2026
- Scheduled Q4 and full-year 2025 results release after U.S. market close
- Conference call time
- 4:30 p.m. Eastern Time
- Management earnings conference call on March 24, 2026
- Reporting periods
- Q4 2025 and FY 2025
- Financial results to be discussed on March 24, 2026
Historical Context
-
Preliminary Q4 and FY2025 results described as challenging with guidance context.
-
Former MaxCyte commercial chief joining Cellares to support its IPO plans.
-
Planned CFO transition in 1H 2026 with assurances on continuity and strategy.
-
Q3 revenue decline and margin pressure while reiterating full‑year 2025 guidance.
-
Preliminary Q3 2025 results with reiterated 2025 guidance and detailed cash levels.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX® gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.
Investor Relations
Gilmartin Group
David Deuchler, CFA
ir@maxcyte.com
Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.